Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Desloratadine is a second-generation tricyclic antihistamine used to relieve symptoms of allergic rhinitis (hay fever), chronic idiopathic urticaria (hives), and pruritus. It is the active descarboethoxy metabolite of loratadine. Desloratadine acts as a selective peripheral H1-receptor antagonist, blocking the action of histamine—a substance in the body that causes allergic symptoms such as sneezing, itching, runny nose, watery eyes, and hives. Because it does not readily cross the blood-brain barrier, desloratadine is considered non-sedating compared to first-generation antihistamines. It may also suppress histamine release from human mast cells[3][5][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on desloratadine.